Prognostic and clinicopathologic significance of circZFR in multiple human cancers

Table 1 Summary of the main characteristics of the included studies

Author	Year	Country	Cancer type	Clinical stage	Sample size	Cut-off value	Follow-up (months)	Detection method	Adjuvant therapy	Survival analysis	Outcome measure	NOS
Cedric, B [15]	2020	China	HCC	T1–T4	62	Mean	–	qRT–PCR	None	Univariate	CP	7
Chen, Z [19]	2020	China	BrC	I–IV	70	Median	60	qRT–PCR	N/A	Univariate	OS, CP	9
Fang, N [23]	2020	China	ESCC	I–IV	58	Median	–	qRT–PCR	None	Univariate	CP	7
Huang, S [21]	2020	China	GC	–	60	N/A	60	qRT–PCR	None	Univariate	OS	8
Huang, W [24]	2020	China	BlC	–	55	Median	60	qRT–PCR	None	Univariate	OS, DFS	8
Li, L [25]	2021	China	HCC	I–III	49	N/A	–	qRT–PCR	None	Univariate	CP	7
Lin, Y [26]	2021	China	HCC	I–IV	50	Median	60	qRT–PCR	None	Multivariate	OS,CP	9
Liu, M [20]	2020	China	BrC	I–IV	65	Median	54	qRT–PCR	None	Univariate	OS, CP	8
Liu, W [16]	2018	China	LC	–	44	N/A	80	qRT–PCR	None	Univariate	OS	8
Luo, L [27]	2021	China	BlC	I–IV	60	N/A	78	qRT–PCR	N/A	Univariate	OS,CP	8
Tan, A [28]	2019	China	HCC	–	80	Mean	60	qRT–PCR	None	Univariate	OS	8
Wei, H [17]	2018	China	PTC	–	41	N/A	60	qRT–PCR	N/A	Univariate	OS	8
Xu, R [29]	2021	China	HCC	I–IV	40	N/A	–	qRT–PCR	None	Univariate	CP	7
Yang, X [30]	2019	China	HCC	I–IV	30	Median	–	qRT–PCR	None	Univariate	CP	7
Zhang, P [22]	2017	China	CRC	I–IV	170	N/A	–	qRT–PCR	None	Univariate	CP	7
Zhang, W [18]	2019	China	BlC	Ta–T4	104	Median	72	qRT–PCR	None	Univariate	OS, PFS, CP	9
Zhan, W [31]	2020	China	HCC	I–IV	60	N/A	100	qRT–PCR	None	Univariate	OS, CP	9

Abbreviations: BlC bladder cancer, BrC breast cancer, CRC colorectal cancer, CP clinicopathological parameters, DFS disease-free survival, ESCC esophageal squamous cell cancer, GC gastric cancer, HCC hepatocellular carcinoma, LC lung cancer, N/A not available, NOS Newcastle-Ottawa Scale, OS overall survival, PFS progression-free survival, PTC papillary thyroid cancer, qRT-PCR quantitative real-time polymerase chain reaction

ISSN: 1477-7819